Skip to content
Review

Darwinian nanomedicine: artificial intelligence-driven evolutionary drug delivery for adaptive and precision therapeutics

Sep 2026 · Drug Development and Industrial Pharmacy · Vol 52, pp. 2107 - 2126 · 0 citations · 141 references
Medicine

TL;DR

Darwinian nanomedicine represents a paradigm shift from static nanoparticle design toward AI-guided adaptive optimization of drug delivery systems, and computationally inspired rather than biological processes.

Abstract

Abstract Objective This review presents Darwinian nanomedicine as an artificial intelligence (AI)-enabled drug delivery strategy that applies Darwinian evolutionary principles as a computational and engineering analogy. Rather than implying biological evolution of nanoparticles, the framework employs iterative cycles of variation, selection, adaptation, and computational inheritance to optimize nanoparticle design through experimental feedback and AI-driven optimization. Significance of review Conventional nanocarrier-based drug delivery systems have improved bioavailability, targeting, and therapeutic efficacy but remain static in design and limited in their ability to accommodate disease heterogeneity and variability. Darwinian nanomedicine represents a framework that integrates artificial intelligence with evolutionary optimization principles to iteratively refine nanoparticle formulations based on experimental performance rather than biological evolution. Key findings Recent studies demonstrate that diverse nanoparticle libraries can be iteratively screened and computationally optimized according to performance. Advances in artificial intelligence, machine learning, high-throughput screening, Bayesian optimization, and evolutionary algorithms have accelerated the identification of nanoparticle formulations with improved targeting efficiency, drug release, stability, and performance through closed-loop design–test–learn workflows. Conclusions Darwinian nanomedicine represents a paradigm shift from static nanoparticle design toward AI-guided adaptive optimization of drug delivery systems. Importantly, the evolutionary processes described in the framework are computationally inspired rather than biological, relying on iterative engineering and experimental optimization instead of nanoparticle self-replication or genetic inheritance. Although significant challenges remain regarding scalability, reproducibility, data standardization, manufacturing, and regulatory approval, continued advances in nanotechnology and artificial intelligence may facilitate the future translation of this framework into precision medicine applications. GRAPHICAL ABSTRACTMulti-panel diagram depicting a seven-step process for developing adaptive nanocarriers in biomedicine.The figure presents a seven-panel process flow for developing adaptive nanocarriers for biomedical applications. Panel 1 illustrates diverse nanoparticle generation by size, charge, composition, and ligands. Panel 2 shows immune cells interacting with nanoparticles during biological selection pressure, including immune clearance and cellular uptake. Panel 3 depicts high-throughput screening methods featuring flow cytometry and AI tools for efficacy evaluation. Panel 4 represents AI and evolutionary algorithms with neural networks linking data and predictions. Panel 5 outlines an iterative evolutionary optimization cycle, highlighting variation, inheritance, selection, and adaptation. Panel 6 illustrates nanoparticles delivering drugs to cells for personalized medicine. Panel 7 summarizes applications in cancer therapy, antimicrobial treatments, and gene delivery through icons.

View source

Similar papers

Review Open access Oct 2026

Artificial Intelligence-Enabled Nanomedicine in Precision Oncology: Diagnosis, Targeted Therapy, and Clinical Translation

Abstract Cancer nanomedicine offers programmable platforms for diagnosis, imaging, drug and gene delivery, and theranostics, but its clinical performance is constrained by tumor heterogeneity, complex nano–bio interactions, and interpatient variability. Artificial intelligence (AI) provides a means to integrate physico...

Ruba Altahla, Yong-Ping Wang, Mahdi Morshedi Yekta et al. · 0 citations
Oct 2026

Nanoemulsion-based Cancer Therapy: Innovations Driven by Artificial Intelligence

Cancer is a significant global health concern, marked by unregulated cell proliferation, tissue damage, and elevated mortality rates. Chemotherapy and radiation are traditional methods that do not target specific cells, which leads to serious side effects and low effectiveness because of drug resistance. Nan...

B. Rane, Aarti V. Udmale, Punam B. Rane et al. · 0 citations
Review Sep 2026

Integrating Artificial Intelligence with Liposomal Nanocarriers for Advanced Drug Delivery.

AI-integrated approaches represent a paradigm shift in liposome development, offering accelerated formulation design, enhanced scalability, and improved prospects for reliable clinical translation.

Pravin Kumar, Sunny Bhardwaj, Ajay Kumar et al. · 0 citations
#gene editing Review Open access Oct 2026

Artificial Intelligence, Microrobots/Nanorobots and Pharmaceutically Optimized Nanocarrier Systems for Precision Tumor Multitargeting

This narrative review critically examines the convergence of artificial intelligence, microrobotic/nanorobotic systems, and pharmaceutically optimized nanocarriers for precision tumor multi-targeting and suggests that integrating AI-guided design, active navigation, and responsive nanocarriers may enhance spatial and t...

Laura Marinela Ailioaie, C. Ailioaie, R. Stan et al. · 0 citations
Review Oct 2026

Artificial intelligence-guided green and circular nanotechnology: designing sustainable, biodegradable, and bioresponsive nanocarriers for next-generation precision drug delivery.

The convergence of artificial intelligence (AI), green chemistry, and nanocarrier-based drug delivery is reshaping pharmaceutical research toward a more sustainable and precision-oriented paradigm. Conventional nanoparticle design strategies have traditionally prioritized biological efficacy while largely overlooking e...

Nabil A. Shoman, Menna M. Abdellatif, Rawan A. Fitaihi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.